Target / Biomarker
Discovery & Validation
Euretos is an AI (Artificial Intelligence) platform used by pre-clinical researchers for in-silico discovery & validation of targets and biomarkers. World leading pharma, biotech and academic institutions use it to accelerate their research. Available as subscription, consulting service or direct access
EURETOS AI PLATFORM
In Silico Multi Omics
Drive your in vitro and in vivo research by in silico multi omics analysis. Ask Euretos and evaluate how molecular mechanisms influence cell and tissue functions, and in turn mediate phenotypes and disease pathology.
FIND OUT MORE
Euretos featured in Nature publication as major example of AI driven hypothesis generationFriday 14 September 2018
Nature has just issued an in-depth article surveying innovative applications that use AI for literature and data exploration. The Euretos AI Platform is featured in the article as an example of how AI technology is already contributing today to the ...
Euretos AI Platform uncovers disease mechanism for novel melanoma targetFriday 07 September 2018
In a recent study published in the Biomedicine & Pharmacotherapy journal, researchers identified TPX2 as a novel potential target for melanoma. The study found that TPX2 promotes the proliferation of melanoma cells and that inhibition of TPX2 d ...
Prof David Webb (The Scripps Research Institute)
“The Euretos AI Platform is nothing less than an in silico way to save all drug and biotech researchers an infinite amount of blood, sweat and tears by providing
them with a powerful knowledge discovery platform.
The Euretos AI Platform allows the researcher to rapidly assess whether a given target, research area, etc., is related, even distantly, to another such entity thus allowing one to uncover hidden connections, leading to new knowledge.In the drug discovery arena, this thing is a gold mine.